{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:16:50Z","timestamp":1792819010119,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.omtm.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T13:39:45Z","timestamp":1647437985000},"page":"137-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["In\u00a0vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria"],"prefix":"10.1016","volume":"25","author":[{"given":"Rebeca","family":"Martinez-Turrillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Martin-Mallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Rodriguez-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Zapata-Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodriguez-Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patxi","family":"San Martin-Uriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Vilas-Zornoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda E.","family":"Calleja-Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Salido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-1866","authenticated-orcid":false,"given":"Juan R.","family":"Rodriguez-Madoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2022.03.006_bib1","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.bbadis.2012.03.004","article-title":"Primary hyperoxalurias: disorders of glyoxylate detoxification","volume":"1822","author":"Salido","year":"2012","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.omtm.2022.03.006_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.03.006_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0014-5793(86)80563-4","article-title":"Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I","volume":"201","author":"Danpure","year":"1986","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtm.2022.03.006_bib4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s004310050649","article-title":"Primary hyperoxaluria type 2","volume":"156","author":"Kemper","year":"1997","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.omtm.2022.03.006_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajhg.2010.07.023","article-title":"Mutations in DHDPSL are responsible for primary hyperoxaluria type III","volume":"87","author":"Belostotsky","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2022.03.006_bib6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ki.2009.237","article-title":"Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1","volume":"76","author":"Fargue","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtm.2022.03.006_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/13543784.2013.741587","article-title":"Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions","volume":"22","author":"Beck","year":"2013","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.omtm.2022.03.006_bib8","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/TP.0b013e31816de49e","article-title":"Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1","volume":"85","author":"Jiang","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.omtm.2022.03.006_bib9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2010.270","article-title":"Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer","volume":"19","author":"Salido","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.03.006_bib10","doi-asserted-by":"crossref","first-page":"14406","DOI":"10.1073\/pnas.1408401111","article-title":"Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1","volume":"111","author":"Miyata","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.omtm.2022.03.006_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00240-017-0998-6","article-title":"A randomised Phase II\/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria","volume":"46","author":"Milliner","year":"2018","journal-title":"Urolithiasis"},{"key":"10.1016\/j.omtm.2022.03.006_bib12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/mt.2016.4","article-title":"Inhibition of glycolate oxidase with dicer-substrate siRNA reduces calcium oxalate deposition in a mouse model of primary hyperoxaluria type 1","volume":"24","author":"Dutta","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.03.006_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1681\/ASN.2016030338","article-title":"An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria","volume":"28","author":"Liebow","year":"2017","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.omtm.2022.03.006_bib14","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.03.006_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bbapap.2005.08.004","article-title":"A preliminary account of the properties of recombinant human Glyoxylate reductase (GRHPR), LDHA and LDHB with glyoxylate, and their potential roles in its metabolism","volume":"1753","author":"Mdluli","year":"2005","journal-title":"Biochim. Biophys. Acta - Proteins Proteomics"},{"key":"10.1016\/j.omtm.2022.03.006_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/science.1138367","article-title":"Evolution of a gene: multiple genes for LDH isozymes provide a model of the evolution of gene structure, function, and regulation","volume":"189","author":"Markert","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.03.006_bib17","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ekir.2021.01.029","article-title":"Hepatic lactate dehydrogenase A: an RNA interference target for the treatment of all known types of primary hyperoxaluria","volume":"6","author":"Ariceta","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.omtm.2022.03.006_bib18","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","article-title":"Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria","volume":"26","author":"Lai","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.03.006_bib19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","article-title":"Safety, pharmacodynamics, and exposure-response modeling results from a first in human phase 1 study of nedosiran in primary hyperoxaluria","volume":"101","author":"Hoppe","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtm.2022.03.006_bib20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omtm.2022.03.006_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.03.006_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2016.10.044","article-title":"CRISPR-based technologies for the manipulation of eukaryotic genomes","volume":"168","author":"Komor","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2022.03.006_bib23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T\u00a0cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.03.006_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T\u00a0cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.03.006_bib25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.03.006_bib26","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1038\/s41467-018-07827-1","article-title":"CRISPR\/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I","volume":"9","author":"Zabaleta","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2022.03.006_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2022.03.006_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.gene.2012.07.009","article-title":"Human thyroxine binding globulin (TBG) promoter directs efficient and sustaining transgene expression in liver-specific pattern","volume":"506","author":"Yan","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.omtm.2022.03.006_bib29","doi-asserted-by":"crossref","first-page":"18249","DOI":"10.1073\/pnas.0607218103","article-title":"Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer","volume":"103","author":"Salido","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.omtm.2022.03.006_bib30","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bbadis.2015.09.016","article-title":"Hydroxyproline metabolism in a mouse model of primary hyperoxaluria type 3","volume":"1852","author":"Li","year":"2015","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.omtm.2022.03.006_bib31","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1681\/ASN.2017040390","article-title":"Hydroxyproline metabolism and oxalate synthesis in primary hyperoxaluria","volume":"29","author":"Fargue","year":"2018","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.omtm.2022.03.006_bib32","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2022.03.006_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature10177","article-title":"In\u00a0vivo genome editing restores haemostasis in a mouse model of haemophilia","volume":"475","author":"Li","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2022.03.006_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In\u00a0Vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.03.006_bib35","doi-asserted-by":"crossref","first-page":"12642","DOI":"10.1038\/ncomms12642","article-title":"Reprogramming metabolic pathways in\u00a0vivo with CRISPR\/Cas9 genome editing to treat hereditary tyrosinaemia","volume":"7","author":"Pankowicz","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2022.03.006_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep44624","article-title":"Somatic genome editing with CRISPR\/Cas9 generates and corrects a metabolic disease","volume":"7","author":"Jarrett","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2022.03.006_bib37","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1038\/s41467-020-16065-3","article-title":"Cas9-AAV6-engineered human mesenchymal stromal cells improved cutaneous wound healing in diabetic mice","volume":"11","author":"Srifa","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2022.03.006_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In\u00a0vivo AAV-CRISPR\/Cas9-Mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.omtm.2022.03.006_bib39","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1002\/ctm2.261","article-title":"Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR\/Cas9 system alleviates primary hyperoxaluria type 1","volume":"10","author":"Zheng","year":"2020","journal-title":"Clin. Translational Med."},{"key":"10.1016\/j.omtm.2022.03.006_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in\u00a0vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2022.03.006_bib41","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in\u00a0vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2022.03.006_bib42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nmeth.3408","article-title":"Off-target mutations are rare in Cas9-modified mice","volume":"12","author":"Iyer","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtm.2022.03.006_bib43","article-title":"Questioning unexpected CRISPR off-target mutations in\u00a0vivo","author":"Sang-Tae","year":"2017","journal-title":"biorxiv"},{"key":"10.1016\/j.omtm.2022.03.006_bib44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.3471","article-title":"Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in\u00a0vivo","volume":"34","author":"Yin","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2022.03.006_bib45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nbt.3469","article-title":"A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice","volume":"34","author":"Yang","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2022.03.006_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In\u00a0Vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.03.006_bib47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2022.03.006_bib48","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1038\/mtna.2014.57","article-title":"Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of pompe disease","volume":"3","author":"Clayton","year":"2014","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.omtm.2022.03.006_bib49","doi-asserted-by":"crossref","first-page":"36283","DOI":"10.1074\/jbc.M112.403360","article-title":"A genetic model of substrate reduction therapy for mucopolysaccharidosis","volume":"287","author":"Lamanna","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2022.03.006_bib50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In\u00a0vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2022.03.006_bib51","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nbt.3628","article-title":"CrispRVariants charts the mutation spectrum of genome engineering experiments","volume":"34","author":"Lindsay","year":"2016","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:27:39Z","timestamp":1762421259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050122000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"alternative-id":["S2329050122000365"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2022.03.006","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}